Abstract:Fragile X syndrome (FXS) is the most common congenital hereditary disease of low intelligence after Down syndrome. Its main pathogenic gene is fragile X mental retardation 1 (FMR1) gene associated with intellectual disability, autism, and fragile X-related primary ovarian insufficiency (FXPOI) and fragile X-associated tremor/ataxia syndrome (FXTAS). FMR1 gene transcription leads to the absence of fragile X mental retardation protein (FMRP). How to relieve or cure disorders associated with FXS has also become a clinically disturbing problem. Previous studies have recently shown that long noncoding RNAs (lncRNAs) contribute to the pathogenesis. And it has been identified that several lncRNAs including FMR4, FMR5, and FMR6 contribute to developing FXPOI/FXTAS, originating from the FMR1 gene locus. FMR4 is a product of RNA polymerase II and can regulate the expression of relevant genes during differentiation of human neural precursor cells. FMR5 is a sense-oriented transcript while FMR6 is an antisense lncRNA produced by the 3′ UTR of FMR1. FMR6 is likely to contribute to developing FXPOI, and it overlaps exons 15–17 of FMR1 as well as two microRNA binding sites. Additionally, BC1 can bind FMRP to form an inhibitory complex and lncRNA TUG1 also can control axonal development by directly interacting with FMRP through modulating SnoN–Ccd1 pathway. Therefore, these lncRNAs provide pharmaceutical targets and novel biomarkers. This review will: (1) describe the clinical manifestations and traditional pathogenesis of FXS and FXTAS/FXPOI; (2) summarize what is known about the role of lncRNAs in the pathogenesis of FXS and FXTAS/FXPOI; and (3) provide an outlook of potential effects and future directions of lncRNAs in FXS and FXTAS/FXPOI researches.

The Microrna Pathway and Fragile X Mental Retardation Protein

The molecular biology of FMRP: new insights into fragile X syndrome

New perspectives on the biology of fragile X syndrome.

Fragile X Mental Retardation Protein Modulates the Stability of Its M6a-Marked Messenger RNA Targets.

Identification of Differentially Expressed Micrornas and Their Target Genes in the Hippocampal Tissues of Fmr1 Knockout Mice.

The Fragile X Mental Retardation Protein Fmrp Plays A Role In The Dna Damage Response

Role of fragile X messenger ribonucleoprotein 1 in the pathophysiology of brain disorders: a glia perspective

Regulation of Synaptic Structure and Function by FMRP-Associated MicroRNAs miR-125b and miR-132

MicroRNA-130b Targets Fmr1 and Regulates Embryonic Neural Progenitor Cell Proliferation and Differentiation

FMRP Acts As a Key Messenger for Dopamine Modulation in the Forebrain

Potential Pharmacological Treatment of Fragile X Syndrome During Adulthood

Fragile X Messenger Ribonucleoprotein Protein and Its Multifunctionality: From Cytosol to Nucleolus and Back

Epigenetic insights into Fragile X Syndrome

Computational Identification and Experimental Validation of MicroRNAs Binding to the Fragile X Syndrome Gene Fmr1

Fragile X Mental Retardation Protein Regulates Proliferation and Differentiation of Adult Neural Stem/Progenitor Cells

FMRP links optimal codons to mRNA stability in neurons

A Chromatin-Dependent Role of the Fragile X Mental Retardation Protein FMRP in the DNA Damage Response

Absence of the Fragile X Mental Retardation Protein results in defects of RNA editing of neuronal mRNAs in mouse

Long Noncoding RNA Can Be a Probable Mechanism and a Novel Target for Diagnosis and Therapy in Fragile X Syndrome

Activity-Dependent Regulation of Release Probability at Excitatory Hippocampal Synapses: A Crucial Role of Fragile X Mental Retardation Protein in Neurotransmission

Circadian Rhythm-Dependent Alterations of Gene Expression in Drosophila Brain Lacking Fragile X Mental Retardation Protein.